| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | GeneticVariation | group | BEFREE | Despite of various PET radioligands targeting the translocator protein TSPO 18-KDa are used for the investigations of neuroinflammatory conditions associated with neurological disorders, development of new TSPO radiotracers is still an active area of the researches with a major focus on the <sup>18</sup>F-labelled radiotracers. | 31257082 | 2019 | ||||
|
0.080 | Biomarker | group | BEFREE | Translocator protein 18 kDa (TSPO) is a validated pharmacological target for the development of new treatments for neurological disorders. | 31268683 | 2019 | ||||
|
0.080 | Biomarker | group | BEFREE | Positron emission tomography (PET) using translocator protein (TSPO) ligands has been used to detect neuroinflammatory processes in neurological disorders, including multiple sclerosis (MS). | 29402285 | 2018 | ||||
|
0.080 | Biomarker | group | BEFREE | Early PET radioligands, such as [<sup>11</sup>C]PK(R)-11195 for the 18-kDa translocator protein (TSPO) and [<sup>11</sup>C]L-deprenyl for monoamine oxidase B, have been used in studies designed to clarify the role of neuroinflammation in a variety of psychiatric and neurological disorders. | 28283959 | 2017 | ||||
|
0.080 | Biomarker | group | BEFREE | The translocator protein (TSPO), formerly known as the peripheral-type benzodiazepine receptor (PBR), is considered an important regulator of steroidogenesis and a potential therapeutic target in neurological disorders. | 28405935 | 2017 | ||||
|
0.080 | AlteredExpression | group | BEFREE | Variations in TSPO expression have been correlated to different diseases, from tumors to endocrine and neurological disorders. | 28771957 | 2017 | ||||
|
0.080 | Biomarker | group | BEFREE | The ability to quantify translocator protein 18 kDa (TSPO) in white matter (WM) is important to understand the role of neuroinflammation in neurological disorders with WM involvement. | 25043159 | 2014 | ||||
|
0.080 | Biomarker | group | BEFREE | Increased binding sites for "peripheral-type" benzodiazepine receptor (PTBR) ligands have been described in a wide range of neurological disorders including both human and experimental epilepsy. | 11893007 | 2002 |